

## Product datasheet for **TR320263**

### AMHR2 Human shRNA Plasmid Kit (Locus ID 269)

#### Product data:

Product Type:	shRNA Plasmids
Product Name:	AMHR2 Human shRNA Plasmid Kit (Locus ID 269)
Locus ID:	269
Synonyms:	AMHR; MISR2; MISRII; MR11
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	AMHR2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 269). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	<a href="#">NM_001164690</a> , <a href="#">NM_001164691</a> , <a href="#">NM_020547</a> , <a href="#">NM_020547.1</a> , <a href="#">NM_020547.2</a> , <a href="#">NM_020547.3</a> , <a href="#">NM_001164691.1</a> , <a href="#">NM_001164691.2</a> , <a href="#">NM_001164690.1</a> , <a href="#">NM_001164690.2</a> , <a href="#">BC126316</a> , <a href="#">BC136356</a>
UniProt ID:	<a href="#">Q16671</a>
Summary:	This gene encodes the receptor for the anti-Mullerian hormone (AMH) which, in addition to testosterone, results in male sex differentiation. AMH and testosterone are produced in the testes by different cells and have different effects. Testosterone promotes the development of male genitalia while the binding of AMH to the encoded receptor prevents the development of the mullerian ducts into uterus and Fallopian tubes. Mutations in this gene are associated with persistent Mullerian duct syndrome type II. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Sep 2009]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).